Notice NOT-OD-24-054 from the NIH Guide for Grants and Contracts

Notice NOT-EB-24-003 from the NIH Guide for Grants and Contracts

Notice NOT-RM-24-001 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-027 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-24-001 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for sites to participate in the Genomic Medicine eConsult Research Network, hereafter referred to as the eConsult Network. The eConsult Network will consist of 2-3 sites working with NHGRI to conduct research on the impact of and methods for implementing regional clinician-to-clinician genomic medicine eConsult services. Specifically, sites will be funded to research how to best design, develop, and implement regional genomic medicine eConsult services; provide outreach to potential users, including those at underserved settings; and assess the impact on key stakeholders while developing successful implementation strategies and resources that can be broadly shared and adopted.

Funding Opportunity PAR-24-106 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support applications from small businesses to develop solutions for commercialization that enable regional genomic medicine eConsult Service.

Funding Opportunity PAR-24-107 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support applications from small businesses to develop solutions for commercialization that enable regional genomic medicine eConsult Service.

Notice NOT-MH-24-115 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-060 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) pre-trial feasibility and acceptability testing of services and service system research relevant to the prevention of substance use. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.

Notice NOT-MH-24-161 from the NIH Guide for Grants and Contracts

Notice NOT-ES-24-005 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-028 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-051 from the NIH Guide for Grants and Contracts

Notice NOT-NR-24-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-103 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-24-102 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-24-094 from the NIH Guide for Grants and Contracts. NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-MH-24-145 from the NIH Guide for Grants and Contracts

Notice NOT-DC-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-MD-24-004 from the NIH Guide for Grants and Contracts